The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagentsSBC: BIOVENTURES, INC Topic: 172
Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: InhiProt Topic: 103
Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health